| 引用本文: | 黎秋萍,郝小庆,刘松.胃肠道脂肪酶抑制剂治疗肥胖的药理药效研究进展——以奥利司他为例[J].中国现代应用药学,2022,39(17):2287-2292. |
| LI Qiuping,HAO Xiaoqing,LIU Song.Research Progress on Pharmacological Effect of Gastrointestinal Lipase Inhibitor in the Treatment of Obesity:Taking Orlistat as an Example[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(17):2287-2292. |
|
| 摘要: |
| 肥胖症是一种由于机体能量过剩导致的慢性代谢性疾病，有可能引起II型糖尿病、心血管病、高血压、中风和多种肿瘤等疾病。目前有多种药物可用于肥胖症治疗，胃肠道脂肪酶抑制剂是当前治疗肥胖症的有效药物。现就胃肠道酶抑制剂及其代表药物奥利司他治疗肥胖的研究进展予以综述，旨在为肥胖症研究及其治疗药物的开发提供参考。 |
| 关键词: 肥胖 奥利司他 胃肠道酶抑制剂 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.17.020 |
| 分类号:R969.3 |
| 基金项目:国家自然科学基金青年基金项目(32100705)；国家临床重点专科建设项目(临床药学)(Z155080000004)；广东省医学科研基金项目(A2021236)；广东省药用功能基因研究重点实验室(中山大学)开放课题基金项目(GDYYGNGY-2021-01) |
|
| Research Progress on Pharmacological Effect of Gastrointestinal Lipase Inhibitor in the Treatment of Obesity:Taking Orlistat as an Example |
|
LI Qiuping1, HAO Xiaoqing1, LIU Song1,2
|
|
1.School of Clinical Pharmacy(School of Integrative Pharmacy, Institute of Integrative Pharmacy Research), Guangdong Pharmaceutical University, Guangzhou 510006, China;2.Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China
|
| Abstract: |
| Obesity is a chronic metabolic disease caused by the excess of energy in body. It may lead to the type II diabetes, cardiovascular disease, hypertension, stroke, and a variety of cancers. At present, many drugs are using for the treatment of obesity. Gastrointestinal lipase inhibitors are the most effective drugs of that. This paper reviewed the research progress of the gastrointestinal lipase inhibitors in the treatment of obesity and its representative drug orlistat, which aimed to provide references for the development of slimming drugs. |
| Key words: obesity orlistat gastrointestinal lipase inhibitors |
